Cwm LLC Lowers Holdings in Guardant Health, Inc. $GH

Cwm LLC trimmed its holdings in Guardant Health, Inc. (NASDAQ:GH) by 27.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,661 shares of the company’s stock after selling 635 shares during the period. Cwm LLC’s holdings in Guardant Health were worth $86,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also made changes to their positions in GH. Janney Montgomery Scott LLC purchased a new position in shares of Guardant Health in the first quarter valued at about $232,000. Teacher Retirement System of Texas purchased a new position in shares of Guardant Health in the first quarter valued at about $866,000. Principal Financial Group Inc. boosted its holdings in shares of Guardant Health by 4,838.8% during the 1st quarter. Principal Financial Group Inc. now owns 498,129 shares of the company’s stock valued at $21,220,000 after purchasing an additional 488,043 shares during the last quarter. GF Fund Management CO. LTD. boosted its holdings in shares of Guardant Health by 22.0% during the 1st quarter. GF Fund Management CO. LTD. now owns 3,164 shares of the company’s stock valued at $135,000 after purchasing an additional 570 shares during the last quarter. Finally, Penserra Capital Management LLC bought a new position in shares of Guardant Health during the 1st quarter valued at about $2,227,000. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on GH shares. Canaccord Genuity Group set a $100.00 price objective on shares of Guardant Health in a report on Thursday. Evercore ISI increased their price objective on shares of Guardant Health from $68.00 to $90.00 and gave the company an “outperform” rating in a report on Thursday. Scotiabank upped their target price on shares of Guardant Health from $57.00 to $60.00 and gave the company a “sector outperform” rating in a research report on Thursday, July 31st. Wells Fargo & Company began coverage on shares of Guardant Health in a research report on Monday, September 22nd. They set an “overweight” rating and a $72.00 target price on the stock. Finally, William Blair reissued an “outperform” rating on shares of Guardant Health in a research note on Thursday, September 25th. Twenty-three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $77.14.

Guardant Health Trading Up 0.7%

NASDAQ GH opened at $93.02 on Monday. The company has a market cap of $11.60 billion, a PE ratio of -28.98 and a beta of 1.53. Guardant Health, Inc. has a 12 month low of $21.85 and a 12 month high of $95.88. The stock has a 50 day moving average of $64.23 and a 200-day moving average of $53.26.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Wednesday, October 29th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.26). The business had revenue of $265.20 million during the quarter, compared to analyst estimates of $235.72 million. During the same period last year, the company earned ($0.88) earnings per share. Guardant Health’s revenue was up 38.5% on a year-over-year basis. Guardant Health has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Insider Transactions at Guardant Health

In related news, CEO Helmy Eltoukhy sold 300,000 shares of the company’s stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $59.45, for a total transaction of $17,835,000.00. Following the completion of the sale, the chief executive officer owned 2,123,499 shares in the company, valued at approximately $126,242,015.55. This represents a 12.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Medina Manuel Hidalgo sold 2,165 shares of the stock in a transaction on Friday, September 12th. The stock was sold at an average price of $54.16, for a total value of $117,256.40. Following the transaction, the director owned 851 shares of the company’s stock, valued at $46,090.16. The trade was a 71.78% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 302,691 shares of company stock worth $17,984,628 over the last three months. Insiders own 6.10% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.